Overview
Are PAH-targeted Therapies Beneficial for CTD-PAH?
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this video-based activity, Dr. Victor Tapson shares the importance of therapy selection for patients with pulmonary arterial hypertension associated with connective tissue disease. Providing real-world insight and key takeaways for application to clinical practice, Dr. Tapson discusses which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team while managing these patients.
This activity is intended for rheumatologists, pulmonologists, cardiopulmonologists, cardiologists, and other clinicians who care for patients at risk for CTD-PAH.
The purpose of this activity is to enhance clinician skills in providing comprehensive and effective treatment for patients with CTD-PAH in order to improve patient outcomes. Through a review of the efficacy and safety data of traditional PAH therapies for treatment of CTD-PAH, this activity provides practical guidance to improve efficacy in patients who previously had attenuated responses to PAH therapies. Key attributes of a successful multidisciplinary team will be shared to enhance patient care.
Upon completion of this activity, participants will be able to:
• Interpret the efficacy and safety data of traditional PAH pharmacotherapies for treatment of CTD-PAH patients
• Apply a collaborative approach across multidisciplinary experts to effectively diagnose and manage CTD-PAH
• Interpret the efficacy and safety data of traditional PAH pharmacotherapies for treatment of CTD-PAH patients
• Apply a collaborative approach across multidisciplinary experts to effectively diagnose and manage CTD-PAH
This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy.
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Victor Tapson, MD
Professor of Medicine, Director Venous Thromboembolism and Pulmonary Vascular Disease Research, Associate Director, Pulmonary/Critical Care
Cedars-Sinai Medical Center
Los Angeles, CA
Purdue University College of Pharmacy requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Victor Tapson, MD (Faculty)
Advisory Board: Actelion Pharmaceuticals US, Inc.; United Therapeutics
Sources of Funding for Research: Actelion Pharmaceuticals US, Inc.; United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL and Purdue University College of Pharmacy staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.